These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12825168)

  • 1. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.
    Chou S; Lurain NS; Thompson KD; Miner RC; Drew WL
    J Infect Dis; 2003 Jul; 188(1):32-9. PubMed ID: 12825168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.
    Chou S; Waldemer RH; Senters AE; Michels KS; Kemble GW; Miner RC; Drew WL
    J Infect Dis; 2002 Jan; 185(2):162-9. PubMed ID: 11807689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
    Chou S; Wechel LC; Marousek GI
    J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
    Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
    Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
    Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
    J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
    Weinberg A; Jabs DA; Chou S; Martin BK; Lurain NS; Forman MS; Crumpacker C; ;
    J Infect Dis; 2003 Mar; 187(5):777-84. PubMed ID: 12599051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
    Scott GM; Weinberg A; Rawlinson WD; Chou S
    Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
    Martin M; Azzi A; Lin SX; Boivin G
    Antivir Ther; 2010; 15(4):579-86. PubMed ID: 20587851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
    Chou S; Marousek G; Li S; Weinberg A
    J Clin Virol; 2008 Sep; 43(1):107-9. PubMed ID: 18502683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
    Chou S; Marousek GI; Van Wechel LC; Li S; Weinberg A
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4160-2. PubMed ID: 17709468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
    Eckle T; Jahn G; Hamprecht K
    J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
    Chou S; Miner RC; Drew WL
    J Infect Dis; 2000 Dec; 182(6):1765-8. PubMed ID: 11069251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of drug-resistant human cytomegalovirus].
    Murayama T
    Nihon Rinsho; 2006 Mar; 64 Suppl 3():508-11. PubMed ID: 16615525
    [No Abstract]   [Full Text] [Related]  

  • 14. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
    Chou S
    J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
    Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
    Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
    Cihlar T; Fuller MD; Mulato AS; Cherrington JM
    Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
    Göhring K; Mikeler E; Jahn G; Rohde F; Hamprecht K
    Antivir Ther; 2008; 13(3):461-6. PubMed ID: 18572760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance.
    Shi R; Azzi A; Gilbert C; Boivin G; Lin SX
    Proteins; 2006 Aug; 64(2):301-7. PubMed ID: 16705640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
    Chou S; Marousek G; Bowlin TL
    Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.